Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab versus mycophenolate mofetil for prevention of NMOSD recurrence
ChiCTR2100043013Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab and mycophenolate mofetil in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: vision, visual field and 6 more. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2100043013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043013.